



## **ACADIA Pharmaceuticals Announces Election of Mary Ann Gray, Ph.D. to Board of Directors**

April 28, 2005

SAN DIEGO, April 28, 2005 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced the election of Mary Ann Gray, Ph.D. to its board of directors on April 27, 2005. The board of directors also appointed Dr. Gray to its audit committee. Dr. Gray will serve as a Class I director and has been nominated by the board to stand for re-election at the annual meeting of stockholders in June 2005.

"We are delighted that Mary Ann Gray has joined ACADIA's board," said Uli Hacksell, Ph.D., Chief Executive Officer of ACADIA. "Her unique blend of Wall Street, financial, and scientific experience in the industry will be a valuable asset as we continue to advance our clinical programs and position ACADIA for future growth."

Dr. Gray succeeds Carl L. Gordon, Ph.D., who resigned from ACADIA's board of directors on April 27, 2005. "Carl Gordon has provided invaluable business guidance during his tenure on our board," said Dr. Hacksell. "We deeply appreciate the many significant contributions made by Carl over the past several years as we leveraged our discovery capabilities to produce a portfolio of product candidates and transitioned to a publicly-held company."

Dr. Gray has more than 20 years of experience in the biotechnology and biopharmaceutical industry. She is currently President of Gray Strategic Advisors, LLC, a biotechnology strategic planning and advisory firm, and serves on the boards of directors of Telik Inc. and Dyax Corp. Previously, she was Senior Analyst and Portfolio Manager for the Federated Kaufmann Fund. Dr. Gray also led biotechnology equity research groups at Raymond James & Associates, Warburg Dillon Read, and Kidder Peabody. Dr. Gray began her career as a scientist focused on new drug development at Schering-Plough and NeoRx Corporation. She holds a Ph.D. in pharmacology from the University of Vermont and completed her post-doctoral work at Northwestern University Medical School and at the Yale University School of Medicine.

### **About ACADIA Pharmaceuticals**

ACADIA Pharmaceuticals is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA currently has four drug programs in clinical development as well as a portfolio of preclinical and discovery assets directed at large unmet medical needs, including schizophrenia, Parkinson's disease, neuropathic pain, and glaucoma. Using its proprietary drug discovery platform, ACADIA has discovered all of the drug candidates in its product pipeline. ACADIA's corporate headquarters is located in San Diego, California and it maintains research and development operations in both San Diego and Scandinavia.

### **Forward-Looking Statements**

This release contains forward-looking statements that involve risks and uncertainties, including statements with respect to the growth of ACADIA and the advancement of its research and clinical programs. Actual events or results may differ materially from those projected in any forward-looking statements due to various factors, including the risks and uncertainties inherent in drug development and commercialization. Among the factors that could cause actual results to differ materially from those indicated by such forward-looking statements are: the results of research, development and clinical trials; the timing and success of submission, acceptance, and approval of regulatory filings; and certain other factors that are detailed in ACADIA's annual report on Form 10-K for the year ended December 31, 2004 filed with the United States Securities and Exchange Commission. In addition, the statements in this press release represent ACADIA's expectations and beliefs as of the date of this release. These forward-looking statements should not be relied upon as representing ACADIA's expectations or beliefs as of any date subsequent to the date of this press release.

### **Contacts:**

ACADIA Pharmaceuticals Inc.

Lisa Barthelemy, Director, Investor Relations

Thomas H. Aasen, Vice President and Chief Financial Officer

(858) 558-2871

Lisa Barthelemy, Director, Investor Relations, or Thomas H. Aasen, Vice President and Chief Financial Officer, both of ACADIA Pharmaceuticals Inc., +1-858-558-2871